用CT和临床数据自动预测口咽癌淋巴结外扩散及预后,准确率超88%。
AMO-ENE: Attention-based Multi-Omics Fusion Model for Outcome Prediction in Extra Nodal Extension and HPV-associated Oropharyngeal Cancer
- 基于3D半监督分割与注意力融合,自动识别淋巴结外扩散
- 2年复发、生存预测AUC最高达88.2%,显著优于基线模型
- 适合放疗/综合治疗患者预后评估,推动精准分期临床应用
淋巴结外扩散(ENE)是人乳头瘤病毒(HPV)相关口咽癌(OPC)的重要预后因素,但目前尚未纳入临床分期标准。尽管已有研究倡导将影像学检测的ENE(iENE)作为阳性病例分期指标,但其临床整合仍受限于分割不一致、淋巴结边缘对比度低及人工标注繁琐等问题。为此,我们提出一个全自动端到端流程,结合CT影像与临床数据,评估淋巴结ENE状态并预测治疗结局。方法包括一种分层3D半监督分割模型,用于从放疗规划CT中检测并勾画iENE;从中提取影像组学与深度特征,训练影像检测的ENE分级分类器。预测的ENE状态进一步评估其预后价值,并与现有分期标准对比。此外,将这些淋巴结特征与原发肿瘤特征融合,构建多模态注意力预测模型,实现动态结局预测。在2009至2020年间接受放疗或化放疗的397例HPV阳性OPC患者内部队列中验证:2年随访时,本方法在转移复发预测上达到88.2%(4.8)的AUC,总生存为79.2%(7.4),无病生存为78.1%(8.6);复发、生存、无病生存的协方差指数分别为83.3%(6.5)、71.3%(8.9)、70.0%(8.1),具备临床决策可行性。
原文摘要 · Abstract (English)
Extranodal extension (ENE) is an emerging prognostic factor in human papillomavirus (HPV)-associated oropharyngeal cancer (OPC), although it is currently omitted as a clinical staging criteria. Recent works have advocated for the inclusion of iENE as a prognostic marker in HPV-positive OPC staging. However, several practical limitations continue to hinder its clinical integration, including inconsistencies in segmentation, low contrast in the periphery of metastatic lymph nodes on CT imaging, and laborious manual annotations. To address these limitations, we propose a fully automated end-to-end pipeline that uses computed tomography (CT) images with clinical data to assess the status of nodal ENE and predict treatment outcomes. Our approach includes a hierarchical 3D semi-supervised segmentation model designed to detect and delineate relevant iENE from radiotherapy planning CT scans. From these segmentations, a set of radiomics and deep features are extracted to train an imaging-detected ENE grading classifier. The predicted ENE status is then evaluated for its prognostic value and compared with existing staging criteria. Furthermore, we integrate these nodal features with primary tumor characteristics in a multimodal, attention-based outcome prediction model, providing a dynamic framework for outcome prediction. Our method is validated in an internal cohort of 397 HPV-positive OPC patients treated with radiation therapy or chemoradiotherapy between 2009 and 2020. For outcome prediction at the 2-year mark, our pipeline surpassed baseline models with 88.2% (4.8) in AUC for metastatic recurrence, 79.2% (7.4) for overall survival, and 78.1% (8.6) for disease-free survival. We also obtain a concordance index of 83.3% (6.5) for metastatic recurrence, 71.3% (8.9) for overall survival, and 70.0% (8.1) for disease-free survival, making it feasible for clinical decision making.
Thank you to arXiv for use of its open access interoperability. PaperDance 不是 arXiv 官方产品;中文卡片由大模型生成,请以原文为准。